NZ727950A - Mesenchymal stromal cells for treating sepsis - Google Patents

Mesenchymal stromal cells for treating sepsis

Info

Publication number
NZ727950A
NZ727950A NZ727950A NZ72795015A NZ727950A NZ 727950 A NZ727950 A NZ 727950A NZ 727950 A NZ727950 A NZ 727950A NZ 72795015 A NZ72795015 A NZ 72795015A NZ 727950 A NZ727950 A NZ 727950A
Authority
NZ
New Zealand
Prior art keywords
cells
mscs
ascs
sepsis
cell
Prior art date
Application number
NZ727950A
Other languages
English (en)
Inventor
Wilfried Dalemans
Eleuterio Lombardo
Robert Dekker
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of NZ727950A publication Critical patent/NZ727950A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
NZ727950A 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis NZ727950A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (1)

Publication Number Publication Date
NZ727950A true NZ727950A (en) 2022-07-01

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ727950A NZ727950A (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Country Status (14)

Country Link
US (2) US20170151284A1 (enExample)
EP (1) EP3160481B1 (enExample)
JP (1) JP6722599B2 (enExample)
KR (1) KR102213527B1 (enExample)
CN (1) CN106573017B (enExample)
AU (1) AU2015283662B2 (enExample)
BR (1) BR112016030758B8 (enExample)
CA (1) CA2953884C (enExample)
IL (1) IL249814B (enExample)
MX (1) MX381544B (enExample)
NZ (1) NZ727950A (enExample)
RU (1) RU2715866C2 (enExample)
SG (1) SG11201610844PA (enExample)
WO (1) WO2016001846A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11518982B2 (en) * 2015-12-01 2022-12-06 Adiposeeds, Inc. Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue
WO2017156235A1 (en) * 2016-03-09 2017-09-14 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
ES2927203T3 (es) 2017-02-28 2022-11-03 Univ De Lorraine Células madre mesenquimales derivadas de la gelatina de Wharton para el tratamiento de la sepsis
WO2019084010A1 (en) 2017-10-26 2019-05-02 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE
US12303534B2 (en) * 2018-06-05 2025-05-20 Medipost Co., Ltd Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
EP3874029B1 (en) * 2018-10-29 2023-08-30 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
US20230086254A1 (en) * 2020-01-30 2023-03-23 Jcr Pharmaceuticals Co., Ltd. Medicinal composition comprising dental pulp-derived cells
JP2024517954A (ja) * 2021-05-13 2024-04-23 プライムジェン ユーエス インコーポレイテッド 肝疾患を治療するための方法および組成物
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ258570A (en) 1992-12-02 1996-06-25 Shell Int Research Azoxycyanobenzene derivatives and plant fungicidal compositions
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
PT1926813T (pt) 2005-09-23 2016-09-06 Consejo Superior Investigacion Populações de células que têm atividade imunorreguladora, método para isolamento e usos
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
CN103648509B (zh) * 2011-03-11 2019-02-22 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
BR112016030758B8 (pt) 2022-10-25
KR102213527B1 (ko) 2021-02-09
US20200376038A1 (en) 2020-12-03
WO2016001846A1 (en) 2016-01-07
EP3160481A1 (en) 2017-05-03
RU2715866C2 (ru) 2020-03-03
IL249814A0 (en) 2017-03-30
BR112016030758A2 (enExample) 2017-08-22
AU2015283662A1 (en) 2017-01-19
MX381544B (es) 2025-03-12
KR20170021343A (ko) 2017-02-27
CA2953884A1 (en) 2016-01-07
JP6722599B2 (ja) 2020-07-15
JP2017520583A (ja) 2017-07-27
AU2015283662B2 (en) 2020-09-24
CA2953884C (en) 2022-12-06
SG11201610844PA (en) 2017-01-27
IL249814B (en) 2020-02-27
US20170151284A1 (en) 2017-06-01
RU2016151738A (ru) 2018-07-30
EP3160481B1 (en) 2020-09-09
BR112016030758B1 (pt) 2021-10-13
RU2016151738A3 (enExample) 2019-01-30
CN106573017A (zh) 2017-04-19
MX2017000142A (es) 2017-07-28
CN106573017B (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
US20200376038A1 (en) Mesenchymal stromal cells for treating sepsis
US20220088084A1 (en) Uses of mesenchymal stem cells
EP3260533B1 (en) Methods for treating radiation or chemical injury
JP6764912B2 (ja) 免疫調節活性を有する細胞集団、その調製方法および使用
EP3160480B1 (en) Mesenchymal stromal cells for treating rheumatoid arthritis
Delgado et al. Uses of mesenchymal stem cells
HK1224333B (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
HK1230927A1 (en) Uses of mesenchymal stem cells
AU2015268704A1 (en) Uses of mesenchymal stem cells

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS; FILING DATE: 23 DEC 2016; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 27 JAN 2017; TITLE: MESENCHYMAL STROMAL CELLS FOR TREATING SEPSIS; FILING DATE: 15 DEC 2021; STATUS: PROPOSED; KIND CODE:

Effective date: 20211215

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20220112

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250521